Delving into GU Oncology, we’re thrilled to spotlight the top voices in the field - as selected by peer survey. Thank you to these experts for their invaluable work in advancing cancer care. Your efforts truly make a difference. 🌟 #GUOncology #LARVOL #Oncology

Just in Kidney Cancer 👉Excellent review by #MartaAmannArévalo Javier Puente on different molecularly defined RCC #kidneycancer & their Rx 👉further research is needed to identify beneficial therapies in these subgroups 👇👇 tinyurl.com/bp632yzb UroToday.com OncoAlert KidneyCAN

Just in Kidney Cancer 👉Excellent review by #AlbertLee James Yu on the role of radiation therapy (SBRT) in the Rx of localized and oligometastatic RCC #kidneycancer👉SBRT use will likely increase in the future 👇👇 tinyurl.com/y3upcu8m UroToday.com OncoAlert KidneyCAN

Just in Kidney Cancer 👉Interesting study by #LunavandenBrink Patricia Zondervan comparing outcomes of radical vs. partial nephrectomy in pts w/ cT1b RCC #kidneycancer👉10-year survival rates were similar between both groups👇 tinyurl.com/bdzm9b5b UroToday.com OncoAlert KidneyCAN

Just in Kidney Cancer 👉Excellent review by Albert Jang, MD @ShilpaOnc on papillary RCC #kidneycancer👉Despite improved outcomes with VEGF-TKIs and ICIs, more dedicated clinical trials to pRCC are urgently needed👇 tinyurl.com/4cpsha2p UroToday.com OncoAlert KidneyCAN Kidney Cancer

Just in Kidney Cancer👉Interesting systematic review by #AlfredoDistante Stijn Muselaers on pt selection for active surveillance of small renal masses #kidneycancer👉Age, cardiovascular index & CKD were associated with⬇️OS👇 tinyurl.com/2ty3dna5 OncoAlert UroToday.com KidneyCAN

Just in Annals of Oncology 👉on the heels of the recent approval of belzutifan in mRCC #kidneycancer , herein we show in a ph2 randomized trial👉more belzutifan (200 mg vs 120 mg QD) was not better👇Link: tinyurl.com/nrsxp8s4 UroToday.com OncoAlert KidneyCAN Huntsman Cancer Institute

Join us👉"Premier symposium on Transformation in Cancer Care Delivery" in Salt Lake City, Feb 17-19👉on new models in cancer care (screening to treatment to survivorship)👉Link: bit.ly/3YhHTc6 @huntsmancancer@UUtah @NeliMUlrich American Cancer Society OncoAlert Oncology Brothers

Just in Med by Cell Press 👉Excellent viewpoint by our trainee, Chadi @chadihc98 👉The novel Zirconium-girentuximab PET-CT is set to change the diagnostic paradigm of ccRCC #kidneycancer (akin to PSMA-PET in #prostatecancer)👇 bit.ly/48LBPgB Georges Gebrael UroToday.com OncoAlert

Have been so impressed w Miguel Zugman. After joining us at City of Hope from Einstein Hospital Israelita, he has been prolific with multiple papers, abstracts & ISTs. He wrote the paper in The Oncologist below & offers terrific insights on this updated data from #TIVO3, pointing to durable benefits

Looking forward to spending the evening after a terrific day at ASCO #GU25 w Rana McKay, MD, FASCO Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky) & Thomas Hutson, DO, PharmD, PhD FACP! Come join us at 6 pm Friday evening at the Marriott Hotels Marquis, just down the street from Moscone!

⭐️ Top 10 #GU25 Influencers so far at ASCO GU. ASCO Neeraj Agarwal, MD, FASCO OncoAlert Toni Choueiri, MD Cristiane D Bergerot Sumanta K. Pal, MD, FASCO Tom Powles Emre Yekedüz Petros Grivas Top 10 highest impressions totaling 50+ million impressions OncoAlert ASCO UroToday.com OncLive.com Gil Morgan, MD Nazli Dizman

Good morning, ASCO #GU25! ☀️ Ready to kick off the third and final day! Starting with the poster session on RCC, penile, and testicular cancer, followed by oral abstracts, biomarkers & adjuvant therapy for RCC, trials in progress, and a case-based session (failure on immuno)

COSMIC-313: Addition of Cabozantinib to Ipi+nivo overcomes M2-like macrophage-mediated immune suppression Laurence Albiges 👇Toni Choueiri, MD Robert Motzer MD UroToday.com KidneyCAN OncoAlert #GU25 ASCO #kidneycancer

Final #CheckMate9ER results (5+ yr FU: N+C > S in 1L #aRCC PFS HR 0.58, OS HR 0.79, ORR 55.7% vs 27.4%. No new safety signals. N+C remains a SOC for untreated aRCC. ASCO #GU25 Robert Motzer MD Tom Powles Memorial Sloan Kettering Cancer Center OncoAlert

Katy Beckermann KEYMAKER-UO3 PhI/II #accRCC after #IO-based tx (>50% >3 prior lines) ➡️ Len/belzutifan higher ORR 47% vs Len/pembro 40% vs pembro/belzut 19% w/higher PFS for len + belzutifan (12.5 mos). OS not mature. Interesting activity for Len/belzutifan #GU25 OncoAlert

Outstanding talk and discussion on emerging treatment landscape of mRCC #kidneycancer by Tian Zhang, MD, MHS 👉 emphasizes the need to personalize treatment in mRCC #kidneycancer 👉next gen trials 👇UroToday.com KidneyCAN OncoAlert Kidney Cancer #GU25 ASCO Andrea Apolo, M.D.

Congrats to Toni Choueiri, MD Robert Motzer MD for developing one of the most effective combinations cabozantinib + nivolumab for mRCC #kidneycancer 👉Checkmate 9ER phase 3 trial👉continued strong OS benefit Tom Powles Laurence Albiges @asco #GU25 OncoAlert UroToday.com KidneyCAN Kidney Cancer 👇

Just in JAMA Network Open👉Flatiron Health Real world Rx data from >8500 pts w/ mRCC #kidneycancer 👉After 2018, only 38% & 14% of pts received 2nd & 3rd line Rx respectively👇bit.ly/41H22dp Thanks to my mentors Umang Swami Sumanta K. Pal, MD, FASCO Neeraj Agarwal, MD, FASCO Cc OncoAlert UroToday.com

🎙 Neeraj Agarwal, MD, FASCO of Huntsman Cancer Institute and Dr. Jeanny Aragon-Ching of Inova Schar Cancer Institute highlight key innovations in GU cancer research from #ASCO25 on a new episode of the #ASCODailyNews Podcast: bit.ly/4elzewZ